Isoxazoline Compound for Fish Ectoparasite Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Ectoparasite infestations, particularly sea lice, pose significant challenges in fish farming, leading to reduced growth, feed conversion efficiency, skin and gill damage, secondary infections, and economic losses due to resistance development in chemotherapeutants and mechanical treatments, with potential adverse effects on non-target species.
Innovation Solution
Oral administration of the isoxazoline compound (S)-3-methyl-N-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)-5-(5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)thiophene-2-carboxamide, or its salts or solvates, at reduced dosages of 0.025 to 0.250 mg/kg/d, preferably 0.025 to 0.125 mg/kg/d, for 7 consecutive days, integrated into medicated fish feed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher dosages of chemotherapeutants are used to treat ectoparasites, then treatment efficacy is improved, but resistance development in parasites worsens and environmental harm increases
Solution Approach 1:
The patent changes the chemical structure parameters of the therapeutant by using a novel isoxazoline compound with specific molecular features (dihydroisoxazole ring, trifluoromethyl group, chlorophenyl substitution) that provide enhanced efficacy at lower doses, thereby reducing environmental impact and resistance development while maintaining treatment effectiveness
Solution Approach 2:
The patent creates a new chemical copy with optimized properties - the isoxazoline compound replicates the therapeutic function of existing chemotherapeutants but with improved efficacy-to-dose ratio, allowing lower dosages to achieve the same or better treatment outcomes with reduced harmful effects
2Reliability
If chemotherapeutants are used to treat sea lice infestations, then parasite reduction is achieved, but unintended effects on non-target crustaceans occur
Solution Approach 1:
The patent applies local quality by designing the isoxazoline compound with specific molecular characteristics (trifluoromethyl group at position 5, chlorophenyl substitution) that confer selective toxicity - the compound targets ectoparasites like sea lice while having reduced activity against non-target crustaceans, achieving localized therapeutic action with minimized collateral damage
3Object-affected harmful factors
If reduced dosages of therapeutants are used, then environmental impact is minimized, but treatment efficacy may be compromised
Solution Approach 1:
The patent achieves this resolution by changing the chemical parameters of the therapeutant to the isoxazoline compound structure, which has enhanced bioactivity and pharmacokinetic properties that enable effective parasite control at lower dosages (0.025-0.250 mg/kg/d), thereby reducing environmental impact while maintaining or improving treatment efficacy
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Ectoparasite infestations in fish farming can pose significant challenges and issues for aquaculture operations. This disclosure generally relates to treatment or control of ectoparasite infestations (such as sea lice infestations) on fish (such as salmonids) using a particular dosing regimen of an isoxazoline. In particular, the dosing regimen includes oral administration of the active ingredient: (S)-3-methyl-N-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)-5-(5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)thiophene-2-carboxamide, including salts, or N-oxide, or solvates thereof, of structural formula at a dosage (i.e., in a dose) of from about 0.025 mg/kg/d to about 0.250 mg/kg/d, preferably at a dosage of from about 0.025 mg/kg/d to about 0.125 mg/kg/d. In particular, the dosing regimen can include oral administration from about 3 to about 10 consecutive days, preferably during 7 consecutive days.